Fiche publication
Date publication
février 2021
Journal
Future oncology (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KLEINCLAUSS François
Tous les auteurs :
Roumiguié M, Paoletti X, Neuzillet Y, Mathieu R, Vincendeau S, Kleinclauss F, Mejean A, Guy L, Timsit MO, Lebret T
Lien Pubmed
Résumé
Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clinical trials involving patients with nonmetastatic castration-resistant prostate cancer was performed. Relevant studies were identified by searching PubMed as well as conference abstracts reporting updated overall survival. Three pivotal trials were identified, SPARTAN (apalutamide), PROSPER (enzalutamide) and ARAMIS (darolutamide), and form the basis of this analysis. All three drugs significantly prolonged metastasis-free survival, prostate-specific antigen response and overall survival versus placebo, and were generally well tolerated. Drug selection will likely be influenced by tolerability/safety and other factors, such as the propensity for drug-drug interactions and the presence of comorbidities, that affect the risk-benefit balance in individual patients.
Mots clés
androgen-receptor antagonist, androgen-receptor inhibitor, apalutamide, darolutamide, enzalutamide, nonmetastatic castration-resistant prostate cancer
Référence
Future Oncol. 2021 Feb 5;:
